Login to Your Account



Clinic Roundup


Tuesday, August 14, 2012

• Protalix BioTherapeutics Inc., of Carmiel, Israel, received clearance from the FDA to begin trials of PRX-102, a candidate for Fabry disease. It plans to begin enrolling patients in a Phase I/II study in the fourth quarter. PRX-102 is designed to potentially be an improved version of currently marketed enzyme replacement therapies for Fabry.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription